Kaken Pharmaceutical and US biopharma Astria Therapeutics have signed an exclusive licensing agreement for navenibart, an investigational long-acting antibody for the prevention of hereditary angioedema (HAE) attacks, granting the Japanese firm development and commercialization rights in Japan. As part of…
To read the full story
Related Article
- Kaken Bags Japan Commercial Rights to KalVista’s HAE Drug
April 10, 2025
BUSINESS
- Bayer/Santen to Launch Eylea Bio-AG on February 2
January 9, 2026
- Nxera Bags Japan, Select APAC Rights to Santhera’s DMD Therapy
January 9, 2026
- Keio Offshoot Taps Alfresa Know-How for Cell Therapy Push, Bets on Dual iPS Strategy
January 9, 2026
- Asahi Kasei Sees Tarpeyo Uptake Outpacing Forecast, Peak Sales Can Be Higher
January 9, 2026
- Rakuten Ramps Up Photoimmunotherapy PIII with Financing, Eyes US Filing in 2028
January 9, 2026
Let’s ditch the stuffy jargon and talk about AI in HR like real humans.One of the biggest myths floating around is that AI is coming to steal our jobs. Newsflash: that’s not happening. Sure, AI can handle the boring stuff…





